ReviewSeminars in cancer biology2018
Emerging biomarkers for cancer immunotherapy in melanoma.
Review in Seminars in cancer biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Cancer medicine · 2020Pooled it
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Article
- The microbiome in cancer.iMeta · 2025Review
- Article
- Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine.Frontiers in pharmacology · 2024Review
- Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.Journal for immunotherapy of cancer · 2023Article
- Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.Immunological reviews · 2023Review
- Potential clinical implications of CD4Journal of translational medicine · 2023Article
- The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms.Cancers · 2022Article
- The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
- Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification.International journal of molecular sciences · 2021Article
- B7 score and T cell infiltration stratify immune status in prostate cancer.Journal for immunotherapy of cancer · 2021Article
- The Ratio of GrzBCancers · 2021Article
- Gene expression and immune infiltration in melanoma patients with different mutation burden.BMC cancer · 2021Article
- Identification of an m6A Regulators-Mediated Prognosis Signature For Survival Prediction and Its Relevance to Immune Infiltration in Melanoma.Frontiers in cell and developmental biology · 2021Article
- Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.Frontiers in immunology · 2021Review
- Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.Frontiers in bioengineering and biotechnology · 2021Article
- Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients.Scientific reports · 2020Article
- A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.Future science OA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The treatment and prognosis of metastatic melanoma has changed substantially since the advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor immune response. Despite the success of these agents, clinically actionable biomarkers to aid patient and regimen selection are lacking. Herein, we summarize and review the evidence for candidate biomarkers of response to ICIs in melanoma. Many of these candidates can be examined as parts of a known molecular pathway of immune response, while others are clinical in nature. Due to the ability of ICIs to illicit dramatic and durable responses, well-validated biomarkers that can be effectively implemented in the clinic will require strong negative predictive values that do not limit patients with who may benefit from ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.